Key statistics dashboard for Apollomics, Inc. (APLM). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements.
Stock Data
| Price | $22.11 |
| Market Cap | $49M |
| Enterprise Value | $45.9M |
| Beta | 1.83 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -2.92 |
| Price / Book | -2.92 |
| P/S | 5.71 |
| EV/EBITDA | -4.85 |
| EV/Sales | 5.40 |
| EV/FCF | -4.43 |
| P/FCF | -4.68 |
| Earnings Yield | -117.55% |
| FCF Yield | -21.36% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 100.00% |
| EBIT Margin | -111.45% |
| EBITDA Margin | -111.45% |
| Operating Margin | -111.45% |
| Net Margin | -128.69% |
| Return on Equity | 288.40% |
| Return on Assets | -162.93% |
| Return on Invested Capital | -1586.77% |
| Return on Capital Employed | -2441.49% |
Financial Health
| Current Ratio | 0.96 |
| Quick Ratio | 0.96 |
| Cash Ratio | 0.52 |
| Debt / Equity | -0.20 |
| Debt / Assets | 9.58% |
| Net Debt / EBITDA | 0.28 |
| Interest Coverage | -145.74 |
Per-Share Data
| Revenue per share | 20.19 |
| Book Value per share | -7.57 |
| Cash per share | 7.78 |
| FCF per share | -24.63 |
| Tangible Book Value per share | -7.57 |
| Dividend per share | 0.00 |
Related companies: ADAP · ANL · ATHA · BLRX · GOVX · ICU · LNAI
Explore sector: Healthcare · Biotechnology
More sections of APLM: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks